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Abstract: Apolipoprotein E (APOE) ε4 allele is a risk factor for developing Alzheimer’s disease. In this 
study, we analyzed longitudinal changes in fluorodeoxyglucose (FDG) uptake between APOE ε4 carriers 
and non-carriers in normal control (NC) and Mild Cognitive Impairment (MCI) subjects from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI). We reported forebrain and limbic regions that 
exhibit APOE ε4-mediated declines in FDG uptake over a 96 month period in subjects with MCI but not 
NCs. Using voxel-based and ROI-based analysis, we compared the longitudinal changes in glucose 
uptake between APOE ε4 carriers and non-carriers from 34 NCs with no cognitive impairment and 48 
subjects with MCI. Parietal, temporal and frontal regions had greater longitudinal decreases in FDG 
uptake in APOE ε4 carriers compared to non-carriers. The Superior parietal lobe, inferior temporal gyrus, 
thalamus, caudate, parahippocampal gyrus, fusiform gyrus and middle temporal gyrus showed greater 
longitudinal decreases in FDG uptake in APOE ε4 carriers compared to non-carriers in subjects with 
MCI but not NC. These findings suggest APOE ε4 genotype is associated with decline in glucose uptake 
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in 
MCI but not NCs. Our work in identifying the brain regions most associated with APOE ε4 related AD 
pathophysiology will improve quantitative FDG imaging as a biomarker in precision medicine. 
Keywords: Functional neuroimaging, FDG, Alzheimer’s Disease, APOE ε4 

1. INTRODUCTION 
Alzheimer’s disease (AD) is characterized by memory loss 
and cognitive decline (Small et al. 2000). Neurological 
signatures of AD include amyloid peptide plaques, 
neurofibrillary tangles, and synaptic dysfunction (Mosconi et 
al. 2010; Thambisetty et al. 2010). Neuroimaging studies 
have found glucose hypometabolism and bilateral 
temporoparietal hypoperfusion in subjects who later develop 
AD (Mosconi, Perani, et al. 2004). 
Previous studies have shown the dose dependent role of 
apolipoprotein E (APOE) ε4 allele as a risk factor for 
developing AD, increasing its risk by 2.6 to 14.9 fold and 
lowering the onset by 7 to 15 years (Farrer et al. 1997; 
Thambisetty et al. 2010). APOE functions in the central 
nervous system by delivering cholesterol to neurons (Liu et al. 
2013). Despite studies relating the ε4 allele to an increased 
risk for developing AD, the molecular etiology underlying 
APOE ε4-mediated risk remains elusive. 
An obstacle in AD research is the lack of biomarkers which 
can be used for the pre-clinical diagnosis and to establish an 
unbiased outcome measure for clinical trials (Jack et al. 2013; 
Lo et al. 2011; Rosén et al. 2013). Neurological changes start 
decades before the first visible symptoms of AD. A recent 
research has suggested using readouts of the core pathology 
of AD, including cerebrospinal fluid levels of tau, 
phosphorylated-tau and β-amyloid (Aβ42), to monitor disease 
progression (Rosén et al. 2013). Work by Chen et al. has 
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Alzheimer’s Disease Neuroimaging Initiative (ADNI). We reported forebrain and limbic regions that 
exhibit APOE ε4-mediated declines in FDG uptake over a 96 month period in subjects with MCI but not 
NCs. Using voxel-based and ROI-based analysis, we compared the longitudinal changes in glucose 
uptake between APOE ε4 carriers and non-carriers from 34 NCs with no cognitive impairment and 48 
subjects with MCI. Parietal, temporal and frontal regions had greater longitudinal decreases in FDG 
uptake in APOE ε4 carriers compared to non-carriers. The Superior parietal lobe, inferior temporal gyrus, 
thalamus, caudate, parahippocampal gyrus, fusiform gyrus and middle temporal gyrus showed greater 
longitudinal decreases in FDG uptake in APOE ε4 carriers compared to non-carriers in subjects with 
MCI but not NC. These findings suggest APOE ε4 genotype is associated with decline in glucose uptake 
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in 
MCI but not NCs. Our work in identifying the brain regions most associated with APOE ε4 related AD 
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1. INTRODUCTION 
Alzheimer’s disease (AD) is characterized by memory loss 
and cognitive decline (Small et al. 2000). Neurological 
signatures of AD include amyloid peptide plaques, 
neurofibrillary tangles, and synaptic dysfunction (Mosconi et 
al. 2010; Thambisetty et al. 2010). Neuroimaging studies 
have found glucose hypometabolism and bilateral 
temporoparietal hypoperfusion in subjects who later develop 
AD (Mosconi, Perani, et al. 2004). 
Previous studies have shown the dose dependent role of 
apolipoprotein E (APOE) ε4 allele as a risk factor for 
developing AD, increasing its risk by 2.6 to 14.9 fold and 
lowering the onset by 7 to 15 years (Farrer et al. 1997; 
Thambisetty et al. 2010). APOE functions in the central 
nervous system by delivering cholesterol to neurons (Liu et al. 
2013). Despite studies relating the ε4 allele to an increased 
risk for developing AD, the molecular etiology underlying 
APOE ε4-mediated risk remains elusive. 
An obstacle in AD research is the lack of biomarkers which 
can be used for the pre-clinical diagnosis and to establish an 
unbiased outcome measure for clinical trials (Jack et al. 2013; 
Lo et al. 2011; Rosén et al. 2013). Neurological changes start 
decades before the first visible symptoms of AD. A recent 
research has suggested using readouts of the core pathology 
of AD, including cerebrospinal fluid levels of tau, 
phosphorylated-tau and β-amyloid (Aβ42), to monitor disease 
progression (Rosén et al. 2013). Work by Chen et al. has 
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risk for developing AD, the molecular etiology underlying 
APOE ε4-mediated risk remains elusive. 
An obstacle in AD research is the lack of biomarkers which 
can be used for the pre-clinical diagnosis and to establish an 
unbiased outcome measure for clinical trials (Jack et al. 2013; 
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study, we analyzed longitudinal changes in fluorodeoxyglucose (FDG) uptake between APOE ε4 carriers 
and non-carriers in normal control (NC) and Mild Cognitive Impairment (MCI) subjects from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI). We reported forebrain and limbic regions that 
exhibit APOE ε4-mediated declines in FDG uptake over a 96 month period in subjects with MCI but not 
NCs. Using voxel-based and ROI-based analysis, we compared the longitudinal changes in glucose 
uptake between APOE ε4 carriers and non-carriers from 34 NCs with no cognitive impairment and 48 
subjects with MCI. Parietal, temporal and frontal regions had greater longitudinal decreases in FDG 
uptake in APOE ε4 carriers compared to non-carriers. The Superior parietal lobe, inferior temporal gyrus, 
thalamus, caudate, parahippocampal gyrus, fusiform gyrus and middle temporal gyrus showed greater 
longitudinal decreases in FDG uptake in APOE ε4 carriers compared to non-carriers in subjects with 
MCI but not NC. These findings suggest APOE ε4 genotype is associated with decline in glucose uptake 
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in 
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and cognitive decline (Small et al. 2000). Neurological 
signatures of AD include amyloid peptide plaques, 
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al. 2010; Thambisetty et al. 2010). Neuroimaging studies 
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risk for developing AD, the molecular etiology underlying 
APOE ε4-mediated risk remains elusive. 
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can be used for the pre-clinical diagnosis and to establish an 
unbiased outcome measure for clinical trials (Jack et al. 2013; 
Lo et al. 2011; Rosén et al. 2013). Neurological changes start 
decades before the first visible symptoms of AD. A recent 
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and non-carriers in normal control (NC) and Mild Cognitive Im airment (MCI) subjects from the 
Alzheimer’s Dis ase Neuroimaging Initiative (ADNI). We reported forebrain and limbic regions that 
exhibit APOE ε4-mediated declines in FDG uptake over a 96 month period in subjects with MCI but not 
NCs. Using voxel-based nd ROI-b sed analysis, we compared the longitudinal changes in glucose 
t  between APOE ε4 carriers and non-car iers from 34 NCs with no c gnitiv  impairment and 48 
subjects with MCI. Parietal, te oral and rontal re ion  ha  greater longitudinal decreases in FDG 
uptake in APOE ε4 carriers compared to on-carriers. The Superior parietal lobe, inferior temporal gyrus, 
thalam s, caudate, parahippocampal gyrus, fusiform gyrus and middl  temporal gyrus showed gre ter 
longitudinal ecreases in FDG upt ke in APOE ε4 arri rs compared to non-carriers in subjects with 
 t t . These findings suggest APOE ε4 genotype is a sociated with decline in glucose uptake 
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in 
MCI but not NCs. Our work in identifying the brain regions most associated with APOE ε4 related AD 
pathophysiology will improve quantitative FDG imaging as a biomarker in precision medicine. 
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1. INTRODUCTION 
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and cognitive decline (Small et al. 2000). Neurol gical 
signatures of AD include amyloid peptide plaques, 
neurofibrillary tangles, and synaptic dysfunctio  (Mosconi et 
al. 2010; Thambisetty et al. 2010). Neuroimaging studies 
have found glucose hypometabolism and bilateral 
temporoparietal hypoperfusion in subjects who later develop 
AD (Mosconi, Perani, et al. 2004). 
Previ us studies have shown the dose dependent role of 
apolipoprotein E (APOE) ε4 allele as  risk f ctor for 
developing AD, increasing its risk by 2.6 to 14.9 fold and 
lowering the onset by 7 to 15 years (Farrer et al. 1997; 
Thambisetty t al. 2010). APOE functions in the c ntral 
nervous syst m by delivering ch l sterol to neurons (Liu et al. 
2013). Despite studies relating the ε4 allele to an increased 
risk for developing AD, the molecular etiology underlying 
APOE ε4-mediated risk remains elusive. 
An obstacle in AD r sea ch is the l ck of biomarkers which 
can be used for the pr -clinical diagnosis and to establish n 
unbiased outcome mea ure for clinical trials (Jack et al. 2013; 
Lo et al. 2011; Rosén et al. 2013). Neur logical changes start 
decades before the first visible symptoms of AD. A recent 
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Abstract: Apolipoprote n E (APOE) ε4 alle e is a risk factor for developing Alzheimer’s disease. In thi
study, we nalyzed lo gitudinal changes in fluorodeoxyglucose (FDG) uptake between APOE ε4 carriers
and non-carrier  in normal control (NC) and Mild Cognitive Impairment (MCI) su jects from the
Alzheimer’s Diseas  Neuroimaging Initiative (ADNI). We repor ed forebrain and limbic regions tha
exhibit APOE ε4-mediated declines in FDG uptake ov r a 96 month peri d in subjects with MCI b t not
NCs. Using voxel-based and ROI-based an lysis, we compared the longitud nal changes i  glucose
uptake between APOE ε4 carriers and non-carriers from 34 NCs wi h no cognit ve impairm nt and 48
subjects with MCI. Parietal, temporal a d frontal regions had greater longitudi al decreases in FDG
uptake in APOE ε4 c riers compared to non-carriers. The Superior parietal lobe, inferior temporal gyrus,
thalamus, caudat , parahippocam al gyrus, fusiform gy us and middle temporal gyrus showed greater
longitudi al decreas  in FDG uptak  in APOE ε4 carriers compared to non-carriers in subjects with
MCI but not NC. These findings suggest APOE ε4 genotype is associated with d clin  in glucos  uptake
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in
MCI but n t NCs. Our work in iden ifying the brain re ions m st associated with APOE ε4 related AD 
pathophy iology will improve qua titative FDG imaging as a biomarker in precision medicine. 
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1. INTRODUCTION 
Alzheimer’s disease (AD) is characterized by m m ry loss
and cognitive decline (Small et al. 2000). Neuro ogical
signatures of AD include amyloid peptide plaques,
neurofibrillary tangles, and synaptic dysfunction (Mosconi t
al. 2010; Thambisetty et al. 2010). Neuroimaging studies
have found glucos  hypometa olism and bilateral
tempor parietal hypop rfusion in subjects who later develop 
AD (Mosconi, Perani, et al. 2004). 
Previous studies have shown the dose dependent r le f
apolipoprotein E (APOE) ε4 allele as a risk factor for
dev loping AD, increasing its risk by 2.6 to 14.9 fold and
lowering the onset by 7 to 15 years (Farrer et al. 1997; 
Thambisetty et al. 2010). APOE functi ns in the cen r  
nervous system by elivering chol sterol to neuro s (Liu et al. 
2013). Despite studies relating th  ε4 allele to an increased
risk for dev loping AD, the mo ecular etiology underlying 
POE ε4-mediated isk rema ns elusive. 
A  obstacle in AD research is the lack of biomarkers w ich
can be used f r the pre-clinical diagnosis and to es ablish an
unbiased outcome measure for clinical trials (J ck et al. 2013;
Lo et al. 2011; Rosén et al. 2013). Neurological changes star
decades before th  first visibl  symptoms of AD. A recent
research has s ggested using readouts of the core pathology
of AD, including cerebrosp nal fluid levels of t u,
hosphorylated-tau and β-amyloid (Aβ42), to mo itor disease
progression (Rosén et al. 2013). Work by Chen et al. has 
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study, we nalyzed lo gitudina  changes in fl orode xyglucose (FDG) uptake between APOE ε4 carriers
and non-carrier  in norm l control (NC) and Mild Cognitive Impairmen  (MCI) su j cts from th
Alzheim r’s Diseas  Neuroimaging Initiative (ADNI). We repor ed forebrain and li bic regions tha
exhibi  APOE ε4-mediat d declines in FDG uptake ov r a 96 month p i d in subjects with MCI b t not
NCs. Using voxel-b sed and ROI-based an lys s, we com a ed the longitud nal changes i  glucose
uptake between APOE ε4 carriers and non-carriers from 34 NCs wi h no cognit ve impairm nt and 48
subjects with MCI. Parietal, tem oral and frontal regions had greater lo gitudi al decreases in FDG
uptake in APOE ε4 c riers compared to non-carriers. The Superior pari tal lobe, inferior temp ral gyrus,
thalamus, caudat , parahippocam al gyrus, fusiform gy u and middle temporal gyrus showed greater
longitudinal decreas  in FDG uptak   APOE ε4 carrier comp red to non-carriers in subjects with
MCI but not NC. These findings suggest APOE ε4 ge otype is associated with d clin  in glucos  uptake
over time and that specific limbic and forebrain structures exhibit APOE ε4-mediated FDG decline in
MCI but n t NCs. Our work in iden ifying the brain re ions m st associated with APOE ε4 related AD 
pathophy iology will improve qua titative FDG imaging as a biomarker in precision medicine. 
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1. INTRODUCTION 
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nd cognitive decline (Small et al. 2000). Neuro ogical
signatures of AD include amyl id peptide plaques,
neurofibrillary tangles, and synaptic dysfuncti n (Mosconi t
al. 2010; Thambisetty et al. 2010). Neuroimaging studies
have found glucos  hypometa olism and bilateral
tempor parietal hypop rfusion in subjects who later develop 
AD (Mosconi, Perani, et al. 2004). 
Previous studies have shown the dose dep ndent r le f
apolipoprotein E (APOE) ε4 allele as a risk factor for
dev loping AD, increasing its risk by 2.6 to 14.9 fold and
lowering the onset by 7 to 15 years (Farrer et al. 1997; 
Thambisetty et al. 2010). APOE functi ns in the cen r
nervous syst m by elivering chol sterol to neuro s (Liu et al. 
2013). Despite studies relating th  ε4 allele to an increased
risk for dev loping AD, the mo ecular etiology underlying 
POE ε4-mediated isk remains elusive. 
A  obstacle in AD research is the lack of biomarkers w ich
can b  used f r pre-clinical diagnosis and to es ablish an
unbiased outcome m as re for clinical trials (J ck et l. 2013;
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revealed that glucose hypometabolism measured through 18F-
fluorodeoxyglucose (FDG) positron emission tomography 
(PET), in combination with other biomarkers, may predict 
conversion to AD. FDG imaging may therefore be a non-
invasive biomarker for AD (Chen et al. 2011, 2016; Mosconi, 
Perani, et al. 2004). 
Functional neuroimaging allows for the characterization of 
APOE-ε4-mediated phenotypic changes in AD, including its 
association with glucose hypometabolism (Rosén et al. 2013). 
Cross sectional studies have used FDG imaging to establish 
the dose-dependent effect of APOE ε4 on hypometabolism in 
non-demented adults (Reiman et al. 1996). Longitudinal 
studies used oxygen-15 PET to compare changes in cerebral 
blood flow (rCBF) in non-demented APOE ε4 carriers and 
non-carriers and found greater longitudinal decline in rCBF 
in APOE ε4 carriers compared to non-carriers in the temporal, 
parietal, and frontal cortices (Thambisetty et al. 2010). 
Existing researches have helped to show APOE-ε4-dose 
dependent associations between rCBF decline and 
hypometabolism. However, a lack of longitudinal FDG 
studies, which are critical to establish the role of APOE in 
increasing the risk of disease over time, still exists. The aim 
of this study is to find out if there are any differences in 
APOE ε4 mediated declines in glucose uptake between 
subjects with mild cognitive impairment (MCI) and normal 
controls (NCs). We investigated regional associations 
between the APOE genotype and longitudinal changes in 
glucose uptake measured using FDG at voxel-based and 
region of interest (ROI) based levels over a 96-month follow-
up period in 34 age-matched NCs and 48 MCI subjects from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI). 
This study would allow us to determine the brain regions 
most sensitive to APOE related changes in FDG uptake. 
2. METHODS 
2.1  Subjects 
We used FDG-PET and neuropsychological data from 34 
NCs with no cognitive impairment and 48 MCI subjects from 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
ranging from 55 to 85 years of age. Subjects were followed 
for up to 96 months (mean = 76.7 months; median = 84 
months). All data were downloaded from the ADNI clinical 
data repository (http://www.loni.usc.edu/ADNI/). A detailed 
explanation of study enrollment criteria and protocols can be 
found at www.adni-info.org. Subjects underwent PET 
scanning and structural magnetic resonance imaging (1.5T or 
3T) every 6 months for a total follow-up period of either 60, 
72, 84 or 96 months depending on the availability of 
neuroimaging data. The FDG PET scans and magnetization-
prepared rapid acquisition gradient echo (MP-RAGE) scans 
were collected. Participants were tracked to detect changes in 
neuropsychological testing over the follow-up period.  
2.2  APOE genotyping 
APOE ε4 genotype information was also downloaded from 
ADNI database. Individuals homozygous and heterozygous 
for the APOE ε4 were grouped as APOE carriers (n=32). All 
other participants were classified as non-carriers (n=50). 
2.3  Neuropsychological testing 
The Neuropsychiatric Inventory (NPI) questionnaire, Global 
Clinical Dementia Rating (CDR), Mini-Mental State 
Examination (MMSE), Functional Assessment Questionnaire 
(FAQ), Alzheimer’s Disease Assessment Scale (ADAS) were 
administered during each scanning visit to assess cognitive 
decline associated with dementia. 
2.4  PET image acquisition and processing 
PET and MRI images were downloaded from 
http://adni.loni.usc.edu/ and processed using Statistical 
Parametric Mapping software (SPM8, Wellcome Department 
of Imaging Neuroscience, London, United Kingdom) and 
MATLAB (The MathWorks Inc.). The downloaded PET and 
MRI images were processed using Statistical Parametric 
Mapping software (SPM8, Wellcome Department of Imaging 
Neuroscience, London, United Kingdom) and MATLAB 
(The MathWorks Inc.). All preprocessed mean PET images 
were coregistered to structural MRI images at each follow-up. 
The MRI images were normalized to standard Montreal 
Neurologic Institute (MNI) space using SPM8 with a MRI 
template provided by VBM8 toolbox, and the transformation 
parameters determined by MRI spatial normalization were 
then applied to the coregistered PET images for PET spatial 
normalization. A total of 34 regions of interest (ROIs) were 
manually drawn on the MRI template using PMOD software 
(PMOD Technologies Ltd., Zürich, Switzerland) in standard 
MNI space. A global cortex was defined as a union of orbital 
frontal, prefrontal, superior frontal, lateral temporal, parietal, 
posterior precuneus, occipital, anterior cingulate, and 
posterior cingulate. The ROI of cerebellum gray matter was 
used as a reference tissue, and the 34 ROIs including 
cerebellum were used as template ROIs for all subjects in the 
standard MNI space. Standard uptake value ratio (SUVR) 
images relative to the cerebellum ROI for FDG were 
calculated in the MNI space (image volume: 121x145x121, 
voxel size: 1.5x1.5x15 mm in x, y, z). Thirty-four ROIs 
defined in MNI space were applied to the SUVR images for 
ROI-based SUVR analysis (Chen et al. 2016). 
In brief, separate PET frames were aligned to one another, 
averaged, reoriented and then interpolated into a standard 
image and voxel size (image volume 160×160×96, 
1.5×1.5×1.5 mm in x, y, z). Lastly, all the PET images were 
smoothed to a uniform resolution of 8 mm in full width at 
half maximum (FWHM). 
2.5  Modeling the longitudinal changes in FDG uptake 
Voxelwise PET statistical analysis of the longitudinal 
changes in FDG uptake between APOE ε4 carriers and non-
carriers in MCI and NC group was performed using SPM8 
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(significance level of 0.005 with cluster volume correction). 
The clusters were assessed using the Talairach atlas brain 
(www.talairach.org). R (R version: 3.1.1, www.r-project.org) 
was used to evaluate the ROI-based longitudinal changes in 
glucose uptake between different APOE groups. In 
consideration of some of subjects having different follow-up 
times and follow-up intervals, only two follow-up scans, 
baseline/24-month follow-up versus the last scan, were used 
for the voxel-wise and ROI-based analyses. This protocol 
was adapted from work by Scarmeas et al (Scarmeas et al. 
2004). To compare longitudinal changes in FDG SUVR in 
the APOE ε4 carriers and non-carriers in MCI and NC 
individuals, a general linear model was used to adjust for sex 
and age at baseline or 24-month follow-up in both voxel-wise 
and ROI-based analysis. 
3. RESULTS 
3.1  Participant characteristics and longitudinal changes in 
neuropsychological performance 
Statistical analysis showed no significant differences between 
the APOE ε4 carriers and non-carriers in age, sex distribution, 
and education level at baseline (p: 0.12-0.90). No statistically 
significant differences were detected between carriers and 
non-carriers at baseline in any neuropsychological tests (p: 
0.18-0.99).  No significant differences in follow-up times 
between APOE ε4 carriers and non-carriers were observed in 
either the NC (p=0.29 for baseline versus last and p=0.21 for 
24 month versus last) and MCI (p=0.90 for baseline versus 
last and p=0.70 for 24 month vs. last) groups. 
A linear mixed effects model was used to adjust the 
performance on the neuropsychological tests for baseline age 
and sex. Longitudinal changes in performance between 
APOE ε4 carriers and non-carriers in both MCI and NC 
groups was also compared (data not shown) from both 
baseline to last and 24 months to last. None of the 
neuropsychological tests produced significant (p>0.05) 
differences in the longitudinal changes between APOE ε4 
carriers and non-carriers over the study period.  
We also compared the diagnosis status (AD, MCI or NC) of 
the study participants at 24 months follow-up and last follow-
up to see if there were differences in the proportion of APOE 
carriers and non-carriers that converted to AD or AD and 
MCI in the NC individuals. P values of the difference in the 
rates of conversion to AD (AD or MCI for the NC group) 
between APOE ε4 carriers and APOE ε4 non-carriers were 
0.15 (two-tailed exact Fisher’s test) and 0.30 (two-tailed chi-
square test) for the NC and MCI group, respectively. 
We then potted a Kaplan-Meier survival curve showing the 
conversion over time in the MCI and NC groups in Figure 1. 
Survival plots representing the percent of cognitively normal 
(for the NC groups) or percent of individuals with MCI (for 
the MCI group) were generated using a Kaplan Meier 
estimate. The survival plots represent the probability of not 
converting to AD for the MCI group and AD or MCI for the 
NC group. 
 
Fig. 1. Survival plots of AD Progression in MCI (A) and NC 
(B) groups respectively.  
In the MCI group, the survival curve shows a cumulative 
survival of 45% for APOE carriers and 54% for non-carriers. 
In the NC group, the survival curve shows a survival of 50% 
for the APOE carriers and 76% for the non-carriers. Both 
these analyses indicate a non-significant trend towards the 
APOE carriers having a decreased chance of survival over 
time, or an increased progression to AD within the follow-up 
period. Note that the survival curves in Figure 1 are quite 
stable from baseline to the 24-month follow-up. In light of 
existing research (Jack et al. 2013) showed that responding 
years before cognitive symptoms associated with AD for 
biomarkers such as FDG. We hypothesized the participants in 
our study may have been observed at earlier stages in which 
changes in diagnosis status from NC to MCI to AD. 
3.2  Voxelwise longitudinal changes in FDG 
The APOE carrier vs non-carrier longitudinal changes from 
baseline scan to the last visit were first evaluated. In the NC 
group, no supra-threshold clusters were detected by SPM. In 
the MCI group regions which demonstrated greater 
longitudinal FDG changes in the APOE ε4 carriers vs non-
carriers included: the inferior parietal (cluster of 1102 voxels, 
peak T = 4.60 at -47 mm, -48 mm, 54 mm in x, y, z), superior 
parietal (cluster of 1706 voxels, peak T = 3.61 at 39 mm, -64 
mm, 51 mm in x, y, z), thalamus and precuneus regions (Fig. 
2, upper row).  
We then compared FDG uptake from baseline to 24 months 
follow-up and found that only one cluster, involving the 
pyramids (peak T = 4.14 at -14 mm, -85 mm, -35 mm in x, y, 
z, p<0.001) and tuber (peak T = 3.74 at -18 mm, -90 mm, -29 
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(significance level of 0.005 with cluster volume correction). 
The clusters were assessed using the Talairach atlas brain 
(www.talairach.org). R (R version: 3.1.1, www.r-project.org) 
was used to evaluate the ROI-based longitudinal changes in 
glucose uptake between different APOE groups. In 
consideration of some of subjects having different follow-up 
times and follow-up intervals, only two follow-up scans, 
baseline/24-month follow-up versus the last scan, were used 
for the voxel-wise and ROI-based analyses. This protocol 
was adapted from work by Scarmeas et al (Scarmeas et al. 
2004). To compare longitudinal changes in FDG SUVR in 
the APOE ε4 carriers and non-carriers in MCI and NC 
individuals, a general linear model was used to adjust for sex 
and age at baseline or 24-month follow-up in both voxel-wise 
and ROI-based analysis. 
3. RESULTS 
3.1  Participant characteristics and longitudinal changes in 
neuropsychological performance 
Statistical analysis showed no significant differences between 
the APOE ε4 carriers and non-carriers in age, sex distribution, 
and education level at baseline (p: 0.12-0.90). No statistically 
significant differences were detected between carriers and 
non-carriers at baseline in any neuropsychological tests (p: 
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either the NC (p=0.29 for baseline versus last and p=0.21 for 
24 month versus last) and MCI (p=0.90 for baseline versus 
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A linear mixed effects model was used to adjust the 
performance on the neuropsychological tests for baseline age 
and sex. Longitudinal changes in performance between 
APOE ε4 carriers and non-carriers in both MCI and NC 
groups was also compared (data not shown) from both 
baseline to last and 24 months to last. None of the 
neuropsychological tests produced significant (p>0.05) 
differences in the longitudinal changes between APOE ε4 
carriers and non-carriers over the study period.  
We also compared the diagnosis status (AD, MCI or NC) of 
the study participants at 24 months follow-up and last follow-
up to see if there were differences in the proportion of APOE 
carriers and non-carriers that converted to AD or AD and 
MCI in the NC individuals. P values of the difference in the 
rates of conversion to AD (AD or MCI for the NC group) 
between APOE ε4 carriers and APOE ε4 non-carriers were 
0.15 (two-tailed exact Fisher’s test) and 0.30 (two-tailed chi-
square test) for the NC and MCI group, respectively. 
We then potted a Kaplan-Meier survival curve showing the 
conversion over time in the MCI and NC groups in Figure 1. 
Survival plots representing the percent of cognitively normal 
(for the NC groups) or percent of individuals with MCI (for 
the MCI group) were generated using a Kaplan Meier 
estimate. The survival plots represent the probability of not 
converting to AD for the MCI group and AD or MCI for the 
NC group. 
 
Fig. 1. Survival plots of AD Progression in MCI (A) and NC 
(B) groups respectively.  
In the MCI group, the survival curve shows a cumulative 
survival of 45% for APOE carriers and 54% for non-carriers. 
In the NC group, the survival curve shows a survival of 50% 
for the APOE carriers and 76% for the non-carriers. Both 
these analyses indicate a non-significant trend towards the 
APOE carriers having a decreased chance of survival over 
time, or an increased progression to AD within the follow-up 
period. Note that the survival curves in Figure 1 are quite 
stable from baseline to the 24-month follow-up. In light of 
existing research (Jack et al. 2013) showed that responding 
years before cognitive symptoms associated with AD for 
biomarkers such as FDG. We hypothesized the participants in 
our study may have been observed at earlier stages in which 
changes in diagnosis status from NC to MCI to AD. 
3.2  Voxelwise longitudinal changes in FDG 
The APOE carrier vs non-carrier longitudinal changes from 
baseline scan to the last visit were first evaluated. In the NC 
group, no supra-threshold clusters were detected by SPM. In 
the MCI group regions which demonstrated greater 
longitudinal FDG changes in the APOE ε4 carriers vs non-
carriers included: the inferior parietal (cluster of 1102 voxels, 
peak T = 4.60 at -47 mm, -48 mm, 54 mm in x, y, z), superior 
parietal (cluster of 1706 voxels, peak T = 3.61 at 39 mm, -64 
mm, 51 mm in x, y, z), thalamus and precuneus regions (Fig. 
2, upper row).  
We then compared FDG uptake from baseline to 24 months 
follow-up and found that only one cluster, involving the 
pyramids (peak T = 4.14 at -14 mm, -85 mm, -35 mm in x, y, 
z, p<0.001) and tuber (peak T = 3.74 at -18 mm, -90 mm, -29 
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mm in x, y, z, p<0.001) of the cerebellum in NC group 
showed differential glucose uptake in the APOE ε4 carriers 
vs non-carriers in the NC group. No significant clusters were 
detected in the MCI group. Note that both the pyramids and 
the tuber were not included in our template cerebellum ROI. 
Lastly, we used FDG scans from 24 months to the last 
follow-up for further investigation. In both the MCI and NC 
groups, we found that clusters in the parietal, temporal, and 
frontal brain regions had greater longitudinal decreases in 
FDG uptake in the APOE ε4 carriers as compared to non-
carriers (Fig. 2, lower row). Clusters involving the superior 
parietal lobe, inferior temporal gyrus, thalamus, caudate, 
parahippocampal gyrus, fusiform gyrus and middle temporal 
gyrus were found to exhibit APOE ε4-related longitudinal 
decreases (that is, the APOE ε4 carriers exhibited greater 
decreases than the APOE ε4 non-carriers in these regions) in 
the MCI group but not in the NC group. The mean SUVR 
images created using SPM in standard MNI space in Fig. 3 
demonstrate that certain limbic and forebrain regions showed 
APOE related longitudinal declines in FDG uptake in the 
MCI group but not NC group. 
 
Fig. 2. Differences in Longitudinal Changes in FDG Uptake 
Between APOE ε4 Carriers and Non-carriers.  
 
Fig. 3. FDG Mean SUVR Image of APOE Carriers and Non-
carriers in MCI and NC group.  
3.3 ROI-based longitudinal changes in FDG 
ROI SUVRs data was used to perform a ROI-based 
longitudinal glucose uptake changes analysis between APOE 
ε4 carriers and non-carriers using a linear mixed model fit by 
REML (restricted or residual maximum likelihood) criterion. 
Sex and baseline age were also included as covariates.  
ROI parietal and caudate were the only two regions that 
showed an APOE ε4-related glucose hypometabolism in the 
MCI group from baseline to the last scan. No regions showed 
significant APOE ε4-related FDG SUVR declines from 
baseline to the last follow-up in the NC group. Consistent 
with the voxelwise analysis, more regions that showed 
greater decrease in FDG uptake in the APOE ε4 carriers were 
detected by using the 24-month scan to the last scan (Table 1). 
The parietal and caudate ROIS were detected only in MCI 
group, the frontal cortex was detected only in NC group, and 
the lateral temporal ROI was detected in both groups. 
4. DISCUSSION 
This study analyzed longitudinal changes in FDG uptake 
between APOE ε4 carriers and non-carriers in NCs and adults 
with MCI. Consistent with existing studies, we found parietal, 
temporal and frontal brain regions had greater longitudinal 
decreases in FDG uptake in the APOE ε4 carriers compared 
to non-carriers (Small et al. 2000). Interestingly, we found 
that the superior parietal lobe, inferior temporal gyrus, 
thalamus, caudate, parahippocampal gyrus, fusiform gyrus 
and middle temporal gyrus showed greater longitudinal 
decreases in FDG uptake in APOE ε4 carriers compared to 
non-carriers in subjects with MCI but not in normal controls. 
Previous studies have linked the APOE ε4 genotype to age-
related decreases in cerebral glucose metabolism and blood 
flow. For example, Thambisetty et al. found, consistent with 
our results, greater longitudinal decline in rCBF in non-
demented APOE ε4 carriers compared to non-carriers in the 
temporal, parietal, and frontal cortices (Thambisetty et al. 
2010). Drzezga et al. compared FDG uptake in APOE ε4 
carriers and non-carriers with AD and found a pattern of 
cerebral hypometabolism in the parietal, temporal, and 
cingulate cortical areas in carriers compared to non-carriers 
(Drzezga et al. 2005). A previous water PET found that 
APOE ε4 carriers exhibited a lower activation in the left 
lingual gyrus and higher activation in the left cuneus, 
precuneas, parahippocampal gyrus, and right precentral gyrus 
(Thambisetty et al. 2010). These results show APOE ε4-
related metabolic changes in the forebrain and limbic regions 
of subjects with AD and confirm the results of our study. 
While previous studies have explored APOE-dependent 
changes in subjects with AD and MCI, these studies have 
largely been cross-sectional (Drzezga et al. 2005; Reiman et 
al. 1996; Roher et al. 2012; Scarmeas et al. 2004). 
Longitudinal studies are powerful in their ability to assess 
AD risk over time rather than at a single time point. To our 
knowledge, our work represents the longest lasting 
longitudinal study on APOE dependent changes in both MCI 
and non-demented individuals. 
To ensure the reliability of our data and appropriateness of 
our follow up period, we analyzed the APOE-related AD 
conversion rates in our data. A Fisher’s test for exactness and 
Chi square test revealed that there is a trend towards APOE 
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carriers having a greater rate of conversion compared to non-
carriers in both the MCI and NC groups. The survival plots in 
Figure 2 show AD conversion over time is consistent with 
work by Bonham et al. showing an approximately 60% 
reduction in survival in APOE carriers compared to 20% for 
non-carriers in non-demented subjects whose baseline age 
was between 70 and 80. Further, several studies have 
supported the dose dependent effects of the APOE genotype 
on AD progression (Jack et al. 2013; Mosconi, Perani, et al. 
2004; Reiman et al. 1996). Taken together, these results 
qualitatively show that our data exhibit baseline and 
longitudinal APOE dose dependent effects that are consistent 
with previous studies. Combined previous and this study, the 
results indicates that the presence of the APOE allele 
increases the risk of developing AD concomitantly with an 
increase in glucose hypometabolism (Mosconi, Nacmias, et 
al. 2004; Mosconi, Perani, et al. 2004). 
In this study, we also assessed the role of APOE ε4 in AD 
risk without the effects of normal aging. As a result, we 
found specific regions that showed APOE-related 
longitudinal decreases in FDG uptake in MCI subjects but 
not in NC individuals. What’s more, we investigated the 
APOE ε4 related glucose uptake changes using voxelwise 
analysis and ROI-based analysis. Because one method is 
data-driven, and other is knowledge-based, these techniques 
complement each other and using them together increases the 
reliability and robustness of our study. 
When comparing the baseline scan to 24 months follow-up 
scan, we found two regions in the posterior cerebellum which 
showed significant longitudinal APOE-related declines in the 
NC group, and no significant regions in the MCI group. We 
found no significant regions with APOE dependent declines 
upon pooling the MCI and NC groups (data not shown). 
These findings are consistent with work by Lo et. al showing 
no APOE dependent decreases in FDG-uptake between 0 and 
36 months follow-up in NC and MCI individuals with similar 
baseline ages as our study (p value between NC and MCI 
baseline ages in our study and Lo et al. was 0.67 and 0.81, 
respectively) (Lo et al. 2011). 
We next considered 24 month scans to the last follow-up 
period and identified significantly more brain regions that 
showed an APOE-dependent change over the follow-up 
period in both the MCI and NC groups. We attempt to 
explain this seemingly arbitrary finding by using the model 
proposed by Jack et al. (Jack et al. 2013) in which several 
core AD biomarkers, including FDG, exist below clinical 
detection thresholds long before and sometimes after 
cognitive impairment can be observed in AD patients (Jack et 
al. 2013). Figure 4 shows a representative graph of FDG 
measurements from the lateral temporal lobe of subjects with 
MCI over the follow-up period. The image shows a turning 
point between APOE carriers and non-carriers at 
approximately 24 months. The data indicates non-significant 
smaller differences in FDG SUVR values at earlier time 
points with a turning point at 24 months by voxelwise and 
ROI-based analysis as noted in the Discussion section. Taken 
together, FDG measurements before 24 months may not 
reliably correlate to Alzheimer’s disease progression. By only 
considering scans 24 months after the first scan, we 
hypothesize that we have reduced the percentage of subjects 
with sub threshold biomarker detection levels, and thereby 
selected the most sensitive time interval to follow 
Alzheimer’s progression using FDG. 
 
Fig. 4. Longitudinal FDG SUVR of Lateral Temporal values 
from MCI subjects at baseline over the follow-up period.  
5. CONCLUSIONS 
We observed greater decline in glucose uptake in APOE ε4 
carriers versus non-carriers, consistent with existing research. 
The superior parietal lobe, inferior temporal gyrus, thalamus, 
caudate, parahippocampal gyrus, fusiform gyrus and middle 
temporal gyrus, show APOE ε4 related longitudinal 
decreases in FDG uptake in individuals with MCI but not NC. 
Our work represents one of the longest FDG studies of AD, 
and captures the most appropriate time period to follow AD 
progression. Our work may improve quantitative FDG 
imaging as an AD biomarker and help to identify the brain 
regions most associated with AD progression. 
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carriers having a greater rate of conversion compared to non-
carriers in both the MCI and NC groups. The survival plots in 
Figure 2 show AD conversion over time is consistent with 
work by Bonham et al. showing an approximately 60% 
reduction in survival in APOE carriers compared to 20% for 
non-carriers in non-demented subjects whose baseline age 
was between 70 and 80. Further, several studies have 
supported the dose dependent effects of the APOE genotype 
on AD progression (Jack et al. 2013; Mosconi, Perani, et al. 
2004; Reiman et al. 1996). Taken together, these results 
qualitatively show that our data exhibit baseline and 
longitudinal APOE dose dependent effects that are consistent 
with previous studies. Combined previous and this study, the 
results indicates that the presence of the APOE allele 
increases the risk of developing AD concomitantly with an 
increase in glucose hypometabolism (Mosconi, Nacmias, et 
al. 2004; Mosconi, Perani, et al. 2004). 
In this study, we also assessed the role of APOE ε4 in AD 
risk without the effects of normal aging. As a result, we 
found specific regions that showed APOE-related 
longitudinal decreases in FDG uptake in MCI subjects but 
not in NC individuals. What’s more, we investigated the 
APOE ε4 related glucose uptake changes using voxelwise 
analysis and ROI-based analysis. Because one method is 
data-driven, and other is knowledge-based, these techniques 
complement each other and using them together increases the 
reliability and robustness of our study. 
When comparing the baseline scan to 24 months follow-up 
scan, we found two regions in the posterior cerebellum which 
showed significant longitudinal APOE-related declines in the 
NC group, and no significant regions in the MCI group. We 
found no significant regions with APOE dependent declines 
upon pooling the MCI and NC groups (data not shown). 
These findings are consistent with work by Lo et. al showing 
no APOE dependent decreases in FDG-uptake between 0 and 
36 months follow-up in NC and MCI individuals with similar 
baseline ages as our study (p value between NC and MCI 
baseline ages in our study and Lo et al. was 0.67 and 0.81, 
respectively) (Lo et al. 2011). 
We next considered 24 month scans to the last follow-up 
period and identified significantly more brain regions that 
showed an APOE-dependent change over the follow-up 
period in both the MCI and NC groups. We attempt to 
explain this seemingly arbitrary finding by using the model 
proposed by Jack et al. (Jack et al. 2013) in which several 
core AD biomarkers, including FDG, exist below clinical 
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considering scans 24 months after the first scan, we 
hypothesize that we have reduced the percentage of subjects 
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Alzheimer’s progression using FDG. 
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Table 1.  ROIs with Greater Decrease of FDG SUVR analysis in APOE ε4 Carriers versus  Non-Carriers 
Region NC group MCI group 
baseline vs. last follow-up  
Parietal (p=0.029) 
 
Caudate (p=0.018) 
24 months vs. last follow-up 
Prefrontal (p=0.032) Lateral Temporal (p=0.045) 
Superior Frontal (p=0.041) Parietal (p=0.001) 
Lateral Temporal (p=0.022) Caudate (p=0.013) 
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